Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

David W. Andrews, Charles Scott, Paul W. Sperduto et al. · The Lancet · 2004 · 2.4K citations

Medicine, Oncology, Radiation Oncology +14

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al. · The Lancet · 2020 · 2K citations

Medicine, Nuclear Medicine, Oncology +17

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.9K citations

Medicine, Oncology, Radiation Oncology +15